Correlation of BRAF and NRAS mutation status with outcome site of distant metastasis and response to chemotherapy in metastatic melanoma

摘要

Background: The prognostic significance of BRAF and NRAS mutations in metastatic melanoma patients remains uncertain, with several studies reporting conflicting results, often biased by the inclusion of patients treated with BRAF and MEK (MAPK) inhibitors. We therefore interrogated a historical cohort of patients free of the confounding influence of MAPK inhibitor therapy.